BiotechTube
Arcturus Therapeutics

Arcturus Therapeutics

ARCT
United States

Arcturus Therapeutics is a pioneer in mRNA therapeutics, leveraging its differentiated LUNAR® delivery and STARR™ self-amplifying mRNA platforms to create a diverse pipeline targeting infectious diseases, rare genetic disorders, and other therapeutic areas. The company achieved a major milestone with the approval and commercialization of its COVID-19 vaccine in Asia, validating its technology and establishing commercial capabilities. With strategic partnerships, including a major collaboration with CSL, Arcturus is advancing multiple clinical and preclinical programs while exploring the broad potential of its mRNA platform beyond vaccines.

arcturusrx.com

ARCT · Stock Price

USD 6.655.30 (-44.35%)
Market Cap: $198.1M

Historical price data

AI Company Overview

Arcturus Therapeutics is a pioneer in mRNA therapeutics, leveraging its differentiated LUNAR® delivery and STARR™ self-amplifying mRNA platforms to create a diverse pipeline targeting infectious diseases, rare genetic disorders, and other therapeutic areas. The company achieved a major milestone with the approval and commercialization of its COVID-19 vaccine in Asia, validating its technology and establishing commercial capabilities. With strategic partnerships, including a major collaboration with CSL, Arcturus is advancing multiple clinical and preclinical programs while exploring the broad potential of its mRNA platform beyond vaccines.

Infectious DiseasesRare Genetic DisordersRespiratory DiseasesMetabolic Disorders

Technology Platform

Proprietary LUNAR® lipid-mediated delivery system and STARR™ self-amplifying mRNA (saRNA) technology for the development of vaccines and therapeutics.

Pipeline

15
15 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
ARCT-2303 + Influenza vaccine + Influenza vaccine, adjuvante...COVID-19Phase 3
ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine + Astra Zene...COVID-19 VaccinesPhase 2/3
ARCT-032Cystic FibrosisPhase 2
ARCT-810OTC DeficiencyPhase 2
ARCT-021 single dose priming + ARCT-021 two lower dose primi...Covid19Phase 2

Opportunities

Significant growth opportunities exist in expanding the saRNA platform into new seasonal and pandemic vaccines, advancing liver-targeted rare disease programs to market, and exploring inhaled mRNA for other respiratory conditions.
The CSL partnership provides capital and validation to aggressively pursue these avenues.

Risk Factors

Key risks include clinical trial failures for lead assets, intense competition in the mRNA space, uncertain commercial demand for COVID-19 vaccines, and the long-term safety profile of the novel saRNA platform.
Execution risk in managing both clinical development and commercial operations is also present.

Competitive Landscape

Arcturus competes with mRNA giants (Moderna, BioNTech/Pfizer) and other biotechs, differentiating primarily through its self-amplifying STARR™ technology which may offer dosing and tolerability advantages. In rare diseases, it competes with gene therapy and protein replacement companies.